Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Doha, Qatar.
Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
BMJ Open. 2019 May 22;9(5):e025808. doi: 10.1136/bmjopen-2018-025808.
A key target of the WHO's 'Global Health Sector Strategy on sexually transmitted infections, 2016-2021' is achieving 90% reduction in (gonorrhoea for short) incidence globally by 2030. Though untreated, gonorrhoea has been linked to infertility, the epidemiology of this infection in infertile populations remains poorly understood and somewhat a neglected area of reproductive health. Our proposed systematic review aims to fill this gap by characterising comprehensively gonorrhoea infection in infertile populations globally.
All available studies of gonorrhoea infection in infertile populations, including infertility clinic attendees, will be systematically reviewed informed by Cochrane Collaboration guidelines. Findings will be reported following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data sources will be searched using broad index terms exploded to cover all subheadings and free text terms with no language or year restriction. Any epidemiological measure in infertile populations based on primary data will be eligible for inclusion. Measures based on different assay types will be extracted as separate studies for different analyses. Only one biospecimen type per assay type will be considered based on a predefined priority order. Samples including fewer than 10 participants or assessing infection in the upper genital tract will be excluded. Quality assessments will be conducted for all measures included in the review. Meta-analyses will be implemented using DerSimonian-Laird random effect models to estimate the mean prevalence of gonorrhoea in infertile populations globally, and stratified by WHO region, assay type, sex, infertility type, infertility diagnosis, among other factors. Detailed heterogeneity assessment will be performed, and potential sources of between-study heterogeneity will be explored using meta-regression. Review will be conducted from 26 March 2018 to 28 July 2019.
An institutional review board clearance is not required as all data are publicly available. The findings will be disseminated through a peer-reviewed publication and international scientific meetings/workshops with key stakeholders.
CRD42018102934.
世界卫生组织“2016-2021 年性传播感染全球卫生部门战略”的一个关键目标是到 2030 年全球淋病发病率降低 90%。尽管未经治疗,淋病已与不孕有关,但在不孕人群中这种感染的流行病学仍知之甚少,且在某种程度上被忽视了生殖健康领域。我们提出的系统综述旨在通过全面描述全球不孕人群中的淋病感染来填补这一空白。
所有关于不孕人群中淋病感染的现有研究,包括不孕诊所就诊者,都将根据 Cochrane 协作组指南进行系统综述。研究结果将按照系统综述和荟萃分析的首选报告项目进行报告。数据来源将使用广泛的索引词进行搜索,这些索引词将扩展到所有副标题和自由文本术语,不限制语言和年份。任何基于原始数据的在不孕人群中进行的流行病学测量都有资格纳入。基于不同检测类型的测量将作为不同的研究进行单独分析。每个检测类型仅考虑一种生物标本类型,这是基于预定义的优先级顺序。将排除每个检测类型的样本少于 10 个参与者或评估上生殖道感染的研究。将对综述中包含的所有措施进行质量评估。Meta 分析将使用 DerSimonian-Laird 随机效应模型实施,以估计全球不孕人群中淋病的平均流行率,并按世卫组织区域、检测类型、性别、不孕类型、不孕诊断等因素进行分层。将进行详细的异质性评估,并通过荟萃回归探索研究之间潜在的异质性来源。综述将在 2018 年 3 月 26 日至 2019 年 7 月 28 日进行。
由于所有数据都是公开的,因此不需要机构审查委员会的批准。研究结果将通过同行评议的出版物和有主要利益相关者参与的国际科学会议/研讨会进行传播。
PROSPERO 注册号:CRD42018102934。